Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster session 01

122P - Can circulating PD-1, PD-L1, pan-BTN3As, BTN3A1, BTN2A1 and BTLA levels enhance prognostic power of serum CA125 in patients with advanced high-grade serous ovarian cancer?

Date

10 Sep 2022

Session

Poster session 01

Topics

Tumour Immunology;  Molecular Oncology

Tumour Site

Ovarian Cancer

Presenters

Lidia Rita Corsini

Citation

Annals of Oncology (2022) 33 (suppl_7): S27-S54. 10.1016/annonc/annonc1037

Authors

L.R. Corsini1, D. Fanale1, C. Brando1, S. Cutaia1, M.C. Di Donna2, U. Randazzo1, L. Magrin1, C. Filorizzo1, V. Gurrera1, A. Fiorino1, E. Pedone1, M. Di Piazza1, A. Dimino1, R. Scalia1, R. Romano2, T.D. Bazan Russo1, V. Chiantera2, A. Russo1, V. Bazan3, J.L. Iovanna4

Author affiliations

  • 1 Surgical, Oncological And Oral Sciences Department, Medical Oncology Section, University of Palermo, 90127 - Palermo/IT
  • 2 Gynecologic Oncology, University of Palermo, 90127 - Palermo/IT
  • 3 Biomedicine, Neuroscience And Advanced Diagnostics, University of Palermo, 90133 - Palermo/IT
  • 4 Centre De Recherche En Cancérologie De Marseille (crcm), Inserm U1068, Cnrs Umr, Aix-Marseille Université and Institut Paoli-Calmettes, Marseille, France, 13288 - Marseille/FR
More

Abstract 122P

Background

The most common subtype of ovarian cancer (OC) is the high-grade serous ovarian carcinoma (HGSOC), accounting for 70-80% of all OC deaths. Although HGSOC is a potentially immunogenic tumor, clinical studies assessing the effectiveness of inhibitors of programmed death protein and its ligand (PD-1/PD-L1) in OC patients so far showed only response rates <15%. However, recent studies revealed an interesting prognostic role of plasma PD-1/PD-L1 and other circulating immunoregulatory molecules, such as the B and T lymphocyte attenuator (BTLA), butyrophilin sub-family 3A/CD277 receptors (BTN3A), and butyrophilin sub-family 2 member A1 (BTN2A1) in several solid tumors. Since evidence showed the prognostic relevance of pretreatment serum CA125 levels in OC, the aim of our study was to investigate if soluble forms of inhibitory immune checkpoints can enhance prognostic power of CA125 in advanced HGSOC women.

Methods

Using specific ELISA tests, we examined the circulating PD-1, PD-L1, pan-BTN3As, BTN3A1, BTN2A1 and BTLA levels in eighty-five pretreated advanced HGSOC patients, correlating them with baseline CA125, age at diagnosis, BMI and peritoneal carcinomatosis. Univariate and multivariate Cox proportional hazard regression models were built to identify significant prognostic factors for Progression-free Survival (PFS).

Results

A multivariate analysis revealed that plasma BTN3A1≤4.75 ng/mL (HR: 1.94; 95% CI: 1.23 to 3.07; p=0.004), age at diagnosis ≤60 years (HR: 1.65; 95% CI: 1.05 to 2.59; p=0.03) and absence of peritoneal carcinomatosis (HR: 2.65; 95% CI: 1.66 to 4.22; p<0.0001) were independent prognostic factors for a longer PFS (≥30 months) in advanced HGSOC women. However, further analyses showed that each circulating immune checkpoint (PD-1>2.48 ng/mL, PD-L1>0.42 ng/mL, pan-BTN3As>13.06 ng/mL, BTN3A1>4.75 ng/mL, BTN2A1>5.59 ng/mL, BTLA>2.78 ng/mL) individually correlated in a statistically significant way with serum CA125>401 U/mL levels, suggesting shorter PFS (<30 months) and poor prognosis.

Conclusions

Plasma PD-L1, PD-1, BTN3A1, pan-sBTN3As, BTN2A1 or BTLA levels could be helpful biomarkers to increase prognostic value of CA125.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.

Funding

Has not received any funding.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.